Associate Professor Michael Hill
Contact information
Research groups
Michael Hill
DPhil
Laboratory Scientific Director
Associate Professor Mike Hill joined the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) in 2009 and is the Laboratory Scientific Director of the Wolfson Laboratories. He has a background in population-based studies and functional studies associated with respiratory and cardiovascular disease.
He manages a team of 40 research and technical staff and is responsible for senior strategic oversight of all aspects of laboratory research within Oxford Population Health. Mike works closely with the department's principal investigators, providing central laboratory support for their clinical trials and observational studies ensuring the scientific integrity of the laboratory work.
Research interests include investigating new biochemical markers and validating analytical methods suitable for large-scale research. Wolfson Laboratories are a UKAS accredited testing laboratory (ISO 17025:2017 No. 2799) with extensive computer automation and a particular expertise in developing reliable high-throughput methods of analysis in clinical chemistry and protein biomarkers.
Mike gained his DPhil at the University of Oxford in 1992 and continued his post-doctoral studies at the Nuffield Department of Clinical Medicine, Oxford and The Wellcome Trust Centre for Human Genetics, Oxford. In 1998, he joined the Division of Medicine at University College London where he led a research group.
Recent publications
-
Risk prediction of ischemic heart disease using plasma proteomics, conventional risk factors and polygenic scores in Chinese and European adults.
Journal article
Mazidi M. et al, (2024), Eur J Epidemiol
-
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2024), N Engl J Med
-
Prospective evaluation of the relevance of Epstein-Barr virus antibodies for early detection of nasopharyngeal carcinoma in Chinese adults.
Journal article
Yang L. et al, (2024), Int J Epidemiol, 53
-
PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations.
Journal article
Holmes MV. et al, (2024), Eur J Prev Cardiol, 31, 1015 - 1025
-
Proteomic Analyses in Diverse Populations Improved Risk Prediction and Identified New Drug Targets for Type 2 Diabetes.
Journal article
Yao P. et al, (2024), Diabetes Care, 47, 1012 - 1019